^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Initial palliative intent therapy for PTCL-NOS; EATL; MEITL and AITL, including Nodal PTCL, TFH, and FTCL and AITL….Ruxolitinib added as a category 2B, other recommended regimen for all subtypes.